Member Info for one4one

Im subcontracting for a big pharma H5n1 collecting tissue samples & a freezer full of wild fowl even though the risks of cross contamination is by-passed by the core cooking temperature of 70c ..actually A I scans 15 million molecules a day & has not found a cure for Alzheimer's yet, haywain vast experience of clinical trials falters as his entry was premature, untill the c/trial produces constant clean efficacy Data "phase 11 6/10 cohorts would be a indicator that the science works

You remain in regression you are not up to date with present times ,you need to upgrade your tool box from imperial to metric "passes the adjustable spanner:-)) re-read the post that upset jinx the cell therapy has evolved further more "chemo" has a part in the jigsaw & there are sciences that are combating the areas of concern around those issues + they are out on parole not confined to the petri dish🐭

I like the avacta science on the grounds of bypassing chemo to the direct target of the tumour cell though a break through is unfolding with car-t using the body's own Natural killer cells.

the first of its kind to advance into clinical trials. The design, based on NK cell receptors, is a "multi-chain" model, which differs from the "single-chain" approach of traditional CAR T cells. In the new multi-chain model, the antigen binding and stimulatory functions are carried on separate chains. One chain directs the T cell to recognize the target on the surface of the cancer cell, while the other triggers the attack once the target is found. This allows the T cell to rest when it's not attacking a tumor, rather than constantly being in an active state. When a tumor antigen is found, the two chains come together, activating the T cell to attack the cancer.

Car-t is still in the infancy stage thou the science is evolving once a cancerous cell surface cleaner and has now a dual action of a tumour buster🐭

the first of its kind to advance into clinical trials. The design, based on NK cell receptors, is a "multi-chain" model, which differs from the "single-chain" approach of traditional CAR T cells. In the new multi-chain model, the antigen binding and stimulatory functions are carried on separate chains. One chain directs the T cell to recognize the target on the surface of the cancer cell, while the other triggers the attack once the target is found. This allows the T cell to rest when it's not attacking a tumour, rather than constantly being in an active state. When a tumor antigen is found, the two chains come together, activating the T cell to attack the cancer.

Https://thatstocksguy.substack.com/p/the-new-oil-fields?utm_source=post-email-title&publication_id=1504413&post_id=194695532&utm_campaign=email-post-title&isFreemail=true&r=4a2sd8&triedRedirect=true&utm_medium=email

Tungsten

To understand why tungsten is irreplaceable, you need to understand what nuclear fusion actually involves.

Inside a working fusion reactor, plasma reaches temperatures above 100 million degrees Celsius. That figure is so large it becomes meaningless without comparison.

The surface of the sun is approximately 5,500°C.

The core of the sun — where its own nuclear fusion reactions occur — is around 15 million degrees. The plasma inside a fusion reactor is roughly seven times hotter than the centre of the sun. Every material known to science would not just melt at that temperature — it would vaporise, instantly and completely, before it ever got close.

Except tungsten.

Tungsten’s melting point of 3,422°C is the highest of any pure metal — significantly higher than the next contenders, rhenium (3,186°C) and osmium (3,033°C).

Trending the end of year results will reveal all as the cash burn smoulders exercising the warrants @ £7.50ps may be financle first aid🐭

Quite understandable as the new tech will compress the new data from the cohorts enrolling, then take into consideration of Autologous 121 custom therapy so putting the trial behind schedule the mm are aware that hemo has breached the timelines🐭

Yes agree opti: enlighten me how many cohorts will be enrolled for the clinical trial ?

There is a few country miles ahead before F/T/Designation i would pencil in phase 11/A of the clinical trial then id look out fore director dealing defending the science As this will reassure the market/investors that Avcata is evolving ....bleep....bleep.....bleep ....collaboration/hostile t/o it could go either way🐭

@Toukankahmoon i get your Drift excuse the pun:-), bulls v bears speculation disguises the hype but in my view play the ball & not the man you raise some good points of view🐭

Snippet of link coutesy of Troajan

Great Western Mining: flavour of the month: Great Western Mining has become one of the more talked-about names recently, with some people wondering whether it could follow the path of Guardian Metal. The first target at 2.7p has already been met. Above that, the next target is the upper boundary of the rising trend channel at around 3.75p, hopefully as soon as the end of next month. It may not be Guardian Metal yet, but technically it does look as though it is trying to build toward something bigger🍒.

I do have a investment interest of the car-t therapy "Autologous which is a custom 121 custom treatment which is costly/can not be scaled up and most important " Time which the cohorts have not got ! but in a second breath the science is evolving " Allogenic " i will say the same investment case has a platform for brain tumours of which is still in the petri dish, this is where Avacta fills the Void,....with the recent adoption of the new CEO christine im sure will be a credit to the avacta Board/ CC also has the wealth of experience of car-t therapy "car-t targets the cell surface/does not penetrate a tumour,

may i thank the forum for their in depth knowledge in this field of expertise i will personally absorbe "Everyday is a school day🐭

Cash runway until 2027 pending phase one of the c/t "positive "traveling to phase 11 avacta are on the radar. clean efficacy data ?

I shall implement a caveat if Mr shears sells as that will default my dividend

Looks like im in good company thanks for all the info/links/ avacta are certainly motoring listing/equity raise over subscribed/ 10m /mind blowing

science & a great entry price i might even take the wife by surprise 🐭

@Aldebaran thankyou for the direction you are like a library 🐭

Cheers for the link likes the quote "Silent in the bloodstream.Active in the tumor." sums up my scribble🐭

Fresh to the forum my beliefs "limited" chemo is powerful as it spreads through the system and cohorts get harsh side effects & the drugs can not tell the difference between c/cells & h/cells as the chemo travels through the body .avacta therapy tries to fix that issue by adding a protective coating when the drug reaches the tumour a enzyme "fap removes the protective coating giving a clear pathway for destruction of the cancerous tumour cell that my brief limited insight🐭

Hemogenyx Pharmaceuticals is entering a pivotal and technically complex phase in the clinical development of its CAR-T therapy candidate, HG-CT-1, targeting Acute Myeloid Leukemia. The early clinical signals—three adult patients successfully infused at a half dose—mark not just a safety checkpoint, but a transition point into a more demanding stage of both clinical execution and manufacturing scalability.

At this juncture, the immediate procedural focus is dose escalation. Moving from half-dose to full-dose cohorts is a standard but critical step in early-phase trials, requiring close monitoring for toxicity, particularly cytokine release syndrome and neurotoxicity, which are commonly associated with CAR-T therapies. Each new patient infused at full dose will generate higher-value data on both efficacy and safety, accelerating the determination of an optimal therapeutic window. Parallel to this, the planned inclusion of paediatric patients introduces additional regulatory and clinical considerations. These younger participants will begin at half dose, reflecting a cautious, ethically grounded approach that mirrors the adult trial design but demands tailored oversight in dosing tolerance and immune response.🐭